Linda Bannister of Edward Jones said Pfizer's earnings beat was driven by greater-than-expected cost controls, adding that she's "pleased with Pfizer's ability to execute on its strategy to divest non-core assets and concentrate" on prescription drugs.
"If you didn't know what company you were listening to, they were all sounding the same" on the fourth-quarter conference calls, said Edward Jones analyst Linda Bannister. "They have good balance sheets, good cash flow (but) these companies are all struggling with the same issues."
Analysts expect Lilly earnings to drop through about 2014 before possibly rebounding with newer revenue sources. Edward Jones analyst Linda Bannister said the company's challenge is sharpened because it will lose revenue sources while raising expenses with late-stage testing of several drugs. Those
Date: Oct 20, 2011
Category: Business
Source: Google
Faster-acting aspirin is Bayer's Rx for flat sales
Edward Jones analyst Linda Bannister expects it to be a tough sell. Consumers are reaching for store brands more often. Sales of store brands grew from nearly 23 percent in 2007 to 32 percent of the $1.2 billion in U.S. sales in the 12 months through March, figures from health data firm IMS Health s
Date: May 23, 2011
Category: Business
Source: Google
Big savings coming from emerging generic drugs, patent expirations
"You are going to see more and more people being pushed to generics," said Linda Bannister, health care analyst with Edward Jones in St. Louis. "For patients, I see a big dividend for the research the drug companies put in in the late 1980s and 1990s."
Date: May 04, 2011
Category: Business
Source: Google
Pfizer's Read Says Units with $18.3 Billion in Sales in Review
Even though some of these businesses are growing, theyre not growing fast enough and theyre not large enough to impact the whole company, said Linda Bannister, an analyst at Edward Jones & Co. in Des Peres, Missouri, in a telephone interview today. With the core thats left, good news in th
Date: May 03, 2011
Category: Business
Source: Google
Pfizer Profit Increases as Drugmaker Continues Review of Units
It wasnt a bad quarter, but it wasnt really a catalyst for investors, Linda Bannister, an analyst at Edward Jones & Co. in Des Peres, Missouri, said in a phone interview today. What people are really waiting for is news from the pipeline and news about further divestitures.
Date: May 03, 2011
Category: Business
Source: Google
J&J Says Profit Fell 23% on Consumer Drug, Hip Recalls
Investors, looking at the recalls, are concerned about this damaging the reputation of J&J, Linda Bannister, an analyst at Edward Jones & Co. in St. Louis. The company needs to make it right, to get these things fixed, to make sure there are no additional recalls and that these products g
Date: Apr 19, 2011
Category: Business
Source: Google
Youtube
Linda Bannister I Nile Sister
Linda Bannister, one of my Nile sisters, is the Chair for Charitable G...